Editorial

Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?

Ricardo J.O. Ferreira1, Robert B.M. Landewé2, and José A.P. da Silva3

In the current issue of The Journal of Rheumatology, Kremer and colleagues1 compare the Clinical Disease Activity Index (CDAI) with a slightly modified Corrona Routine Assessment of Patient Index Data 3 (cRAPID3) in terms of correlation and disease activity categorization, using 2 large US registries of patients with rheumatoid arthritis (RA). Overall, a low concordance between these 2 composite indices (κ = 0.29) was found in terms of disease activity categories, despite a moderate correlation between their numerical global scores (rs = 0.58 and 0.72, for the BRASS and CORRONA registries, respectively). The authors provided a correlation matrix of the individual components of these indices, confirming an overall low (rs ≤ 0.50) agreement between physician- and patient-derived domains. The agreement in the classification of patients according to disease activity categories was poor: 34% of all patients in remission or low disease activity (LDA) according to CDAI (n = 28,991) in the CORRONA registry were classified as moderate or high disease activity by cRAPID3. Conversely, among all patients in a “satisfactory” state according to cRAPID3 (n = 22,201), 14% did not reach the target of remission or LDA by the CDAI. The authors concluded that “RAPID3 should not be used as an exclusive measure to evaluate clinical status and inform treatment decisions as the individual components of this metric are highly associated with noninflammatory conditions...and are discordant with CDAI evaluations.”1

These results are striking in a treat-to-target (T2T) era and justify the authors’ conclusion. Treating to target has become a predominant paradigm in the management of RA, supported by statistical evidence of superior efficacy and better long-term outcomes.2,3 The provisional definitions of remission, the primary target, endorsed by the American College of Rheumatology and the European Alliance of Associations for Rheumatology (ACR/EULAR)4 in 2011 (Figure 1), were primarily designed for use in clinical trials. However, their application in clinical practice was already predicted in the pivotal paper4 and actually became widespread, especially in Europe. This makes the definition of “target” a crucial issue.

The concept of clinical remission is meant to represent a status in which “functional and structural outcomes are maximized,” this being most guaranteed in “the absence of signs and symptoms of significant inflammatory disease activity.”5 The ideal definition of target would be stringent enough to entice clinicians to seek the best possible control of inflammation but should also avoid excessive rigor, given the risk of unjustified overtreatment.

All the definitions of remission endorsed by ACR/EULAR include the patient global assessment of disease activity (PtGA). This variable, measured on a visual analog scale of 0–10 cm, has the same weight as the tender and swollen 28-joint counts (TJC28, SJC28), and C-reactive protein (mg/dL). A PtGA of 2 excludes remission in the Boolean definition and a score of 3 excludes remission in the clinical definition and a score of 4 excludes remission in the composite definition.

See RA, CDAI, and RAPID3, page xxx
makes it virtually impossible in all 3 endorsed definitions and in RAPID3. This relative weight is significantly higher than attributed in the original Disease Activity Score in 28 joints (DAS28). Compelling evidence, supported by systematic literature reviews, confirms that PtGA is the most important factor impeding patients from reaching the Boolean definition of remission. This condition, named PtGA-near-remission, affects around 20% of all patients with RA and 45–60% of all those who are otherwise in remission, both in clinical practice6 (n = 23,297) and in trials7 (n = 5792).

Does PtGA reflect disease activity closely enough to justify this effect in the current definition of target and ensure management decisions? The ACR/EULAR Committee justified the inclusion of PtGA in the definitions because it separates active treatment from placebo in clinical trials.4 In fact, several studies have demonstrated that PtGA has a statistically significant positive correlation with more objective measures of disease activity,8,9,10,11 an observation replicated by Kremer, et al.1 Does PtGA reflect disease activity closely enough to justify this effect in the current definition of target and ensure management decisions? The ACR/EULAR Committee justified the inclusion of PtGA in the definitions because it separates active treatment from placebo in clinical trials.4 In fact, several studies have demonstrated that PtGA has a statistically significant positive correlation with more objective measures of disease activity,8,9,10,11 an observation replicated by Kremer, et al.1

However, this correlation is simply absent in the low levels of disease activity,8,9 where the categorical definitions leading T2T decisions become critical. At this level, PtGA is not related to disease activity but rather to fatigue, pain, function, and psychological well-being.8,9,11 Curtis, et al.,12 also using data from the CORRONA registry, revealed that despite the achievement of a meaningful clinical response (decrease ≥ 10 in CDAI) with a biological agent, many patients failed to exceed the minimum clinically important difference in PtGA, pain, function, and fatigue. Boone, et al clearly depicted, through a 3-year prospective cohort study (n = 330, established RA), that despite a statistically significant decrease in DAS28 over time, the RAPID3 remained stable.13 These authors also observed that RAPID3 is poorly associated with DAS28 based on erythrocyte sedimentation rate (ESR) in daily practice, mainly due to the weak associations between RAPID3 and the objective components of DAS28 (SJC28 and ESR)14; these results are confirmed in the current work by Kremer, et al.1

Figure 1. Disease activity measures used in RA. This shows the components and scoring algorithms of 4 disease activity tools currently in use in clinical practice and in clinical trials in RA. They are presented in chronologic order of development. Although the DAS with 28-joint counts was developed in 1995, its original form with 68/66-joint counts was developed in early 80s. ACR: American College of Rheumatology; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28-CRP4v: Disease Activity Score in 28 joints using CRP and 4 variables; ln: natural logarithm; EULAR: European League Against Rheumatism; MDHAQ: multidimensional Health Assessment Questionnaire; PtGA: patient global assessment; PGA: physician global assessment; RA: rheumatoid arthritis; RAPID3: Routine Assessment of Patient Index Data 3; SDAI: Simplified Disease Activity Index; SJC28: swollen 28-joint count; TJC28: tender 28-joint count.
compelling argument against the concept that a useful and valid definition of remission can be based solely on patient-reported outcome measures (PROMs), as conveyed by RAPID3. They actually question whether any of these PROMs, with emphasis on PtGA, should be part of a definition used to guide and target immunosuppressive therapy.

Of course, it would be totally inappropriate to exclude the patient’s perspective from the guidance of therapy, which must remain core to the objectives of medical care. However, we must keep in mind that the current target is blurred by PtGA, exposing patients to the risk of overtreatment, and also that controlling the disease process does not guarantee remission of the effect of disease. This indicates that the patient’s perspective is better served by a separate target, guiding remission of effect/symptoms, once disease remission has been achieved.

This is the foundation for our dual target proposal, with one target focusing on the control of the inflammatory process and the other on the optimization of the patient’s condition. Michaud, et al. recently concluded that “the use of patient-reported outcomes in addition to a treat-to-target approach may provide information that will inform a management decision necessary to address residual symptoms.” Based on data from the “Care in Early RA” (CareRA) trial, Pazmino, et al.suggest that PtGA, pain, function, and fatigue “represent a separate aspect of the disease burden of patients with early RA, which could be further explored as a target for care apart from disease activity.” Selecting the best tools to represent each target seems to be a timely task for the rheumatology community. RAPID3 deserves to be a candidate for the definition of the patient’s target, in parallel with other instruments, such as the Patient Experienced Symptom State (PESS) or the RA Impact of Disease (RAID), but certainly not for the target guiding immunosuppressive therapy. This debate should distinguish clearly the application of these definitions in clinical trials and in clinical practice and be informed by the limitations of multidimensional composite indices in the care of individual patients.

In conclusion, the evidence seems mature enough to advise a revision of the definition of treatment target(s) in RA. PtGA (as other PROMs) can be either a “friend,” if clearly understood by patients and physicians and used according to their intrinsic meaning and psychometric properties, or a “foe” if these conditions are not met, as in composite measures used to guide immunosuppressive therapy. We believe that the consideration of a separate, symptom-based target, would sharpen the definition of remission and foster improved person-centered outcomes beyond disease control.

REFERENCES


6. Ferreira RJ, Santos E, Gossec L, da Silva JA. The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this? Semin Arthritis Rheum 2020;50:583-5.


